Unlock stock picks and a broker-level newsfeed that powers Wall Street.

IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche
IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche · Investor's Business Daily

In This Article:

TG Therapeutics rallied Wednesday after Roche's rival multiple sclerosis treatment, Ocrevus, missed its mark in a study.